Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06533644 · ClinicalTrials.gov registry record · Phase 2

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Syncromune.

Recruiting
Registry status
Phase 2
Development phase
70
Enrollment target
9
Study locations

NCT06533644: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Syncromune.

NCT06533644 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Syncromune. The registered enrollment target is 70 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (64% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06533644, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Syncromune.

RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
9
Study locations

Study Summary

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • PROCEDURE Partial Oncolysis
  • DRUG SV-102

Study Locations (9)

New York

  • Northwell Health - Lake Success
  • Weill Cornell - New York

Arizona

  • University of Arizona Cancer Center - Tucson

Illinois

  • Duly Health - Lisle

Kansas

  • Wichita Urology - Wichita

Michigan

  • Michigan Institute of Urology - Troy

Missouri

  • Mercy Hospital - St Louis

Nebraska

  • University of Nebraska Medical Center - Omaha

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-05-29
Est. Completion 2027-12-14
Phase Phase 2
Syncromune

1 total trials

What NCT06533644 shows while recruiting

NCT06533644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Partial Oncolysis is the first listed.

NCT06533644 lists 9 locations in 8 states (New York, Arizona, Illinois).

Frequently Asked Questions

What is clinical trial NCT06533644 about?

NCT06533644 is a clinical study titled "A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer". The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

What is the current status of trial NCT06533644?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-05-29. Estimated completion is 2027-12-14.

What conditions does trial NCT06533644 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06533644?

The interventions under investigation include: Partial Oncolysis (PROCEDURE), SV-102 (DRUG).

Who is sponsoring clinical trial NCT06533644?

This trial is sponsored by Syncromune, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06533644 being conducted?

This trial has 9 study locations across Arizona, Illinois, Kansas, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06533644's enrollment target sits among peer trials

70 36th of 69 higher than 34 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06533644

Source: ClinicalTrials.gov NCT06533644, the US trial registry maintained by the National Library of Medicine. NCT06533644 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.